Clinical trials: asthma
Asthma
Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
The purpose of this trial is to confirm if benralizumab can reduce the use of maintenance OCS in systemic corticosteroid dependent patients with severe refractory asthma with elevated eosinophils.
- Trial name
- NCT02075255
- Testing
- Benralizumab
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
Asthma
Study to Assess Effect of Device and Formulation on Pharmacokinetics (PK) of AZD1402
To evaluate and compare the pharmacokinetics profiles of AZD1402 after oral inhalation as an inhalation powder and a nebuliser solution.
- Trial name
- NCT03921268
- Testing
- AZD1402
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma
A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma
The purpose of this study is to assess the safety and effects (good and bad) of golimumab therapy in patients with severe, persistent asthma.
- Trial name
- NCT00675649
- Testing
- CNTO 148 / Golimumab
- Sponsor
- Centocor, Inc.
Asthma
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to…
- Trial name
- NCT01025648
- Testing
- E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma
GSK3772847, an anti-interleukin (IL)33 receptor monoclonal antibody, is a novel treatment for asthma. This is a phase 2a study which aims to evaluate efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD)…
- Trial name
- NCT03207243
- Testing
- GSK3772847, Fluticasone propionate/salmeterol, Fluticasone propionate
- Where
- 64 sites in United States, Australia and 4 more
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Bronchial Asthma
BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients
The purpose of this study is to demonstrate the pharmacodynamic bioequivalence of the test product to the reference product in adult patients with asthma.
- Trial name
- NCT03394989
- Testing
- Fluticasone propionate/salmeterol 100/50 µg, Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT
- Where
- United States
- Volunteers
- 1,366 people
- Sponsor
- Cipla Ltd.
Asthma
A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug
Mepolizumab (SB-240563) is a humanized monoclonal antibody (Immunoglobulin G1, kappa, mAb) that blocks human interleukin-5 (hIL-5) from binding to the interleukin (IL)-5 receptor complex expressed on the eosinophil cell surface…
- Trial name
- NCT03014674
- Testing
- Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
The purpose of this study is to assess the PD equivalence of the approved asthma combination therapy, BDA, delivered using the proposed replacement propellant HFO compared with BDA delivered using the currently approved…
- Trial name
- NCT06502366
- Testing
- BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg
- Where
- 128 sites in United States, China and 4 more
- Volunteers
- 424 people
- Sponsor
- AstraZeneca
Asthma
Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants
The main goal of the study is to assess the effect of the administration of reference propellant [HFA-134a (1,1,1,2 - Tetrafluoroethane)] and test propellant [HFA-152a (1 - Difluoroethane)] in healthy adults on mucociliary…
- Trial name
- NCT06506266
- Testing
- HFA-152a, HFA-134a, Radiolabeled saline solution
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteer Study, Healthy Adults
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma.
- Conditions
- Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
- Trial name
- NCT07660731
- Testing
- PF-08103402, Midazolam
- Where
- 2 sites in United States, Belgium
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma Severe Persistent Controlled
Phase I Clinical Trial of TQC2731 Injection
This is the first-in-human phase 1 trial of TQC2731 injection in healthy subjects and in patients with severe asthma to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity.
- Trial name
- NCT04923607
- Testing
- TQC2731
- Where
- China
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Asthma
CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.
To compare a stable dose of salmeterol/fluticasone propionate with a variable dose of formoterol/budesonide where the dose is adjusted according to a physician-guided self-management plan
- Trial name
- NCT00479739
- Testing
- Salmeterol/fluticasone propionate or formoterol/budesonide
- Where
- 106 sites in Australia, Austria and 13 more
- Volunteers
- 700 people
- Sponsor
- GlaxoSmithKline
Asthma
Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)
This is a year-long study evaluating the efficacy of both daily and intermittent treatment of asthma in children who experience symptoms episodically (i.e., seasonally, usually in the context of upper respiratory tract infection).
- Trial name
- NCT00337675
- Testing
- montelukast sodium
- Volunteers
- 1,771 people
- Sponsor
- Organon and Co
Asthma
Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma
Trial to assess asthma exacerbation through to the end of the study; and to demonstrate that the efficacy over one season against culture-confirmed influenza-illness; and finally to assess the safety and tolerability of CAIV-T in…
- Trial name
- NCT00192257
- Testing
- CAIV-T and TIV
- Where
- 2 sites in Belgium
- Volunteers
- 2,229 people
- Sponsor
- MedImmune LLC
Asthma
Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
- Trial name
- PASSAGE (NCT05329194)
- Testing
- Tezepelumab
- Where
- 37 sites in United States
- Volunteers
- 286 people
- Sponsor
- AstraZeneca
Asthma
Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma
The objective of this multicenter, single-arm, open-label clinical study is to evaluate the safety of performing bronchial thermoplasty with the Alair® System during two treatment sessions to treat severe asthma.
- Trial name
- 3to2 (NCT00803088)
- Testing
- The Alair System
- Sponsor
- Boston Scientific Corporation
Eosinophilic Esophagitis
24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)
This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (EoE) followed by a single-arm, open-label extension.
- Trial name
- NCT05634746
- Testing
- APT-1011, Esophagogastroduodenoscopy
- Where
- 60 sites in United States, Canada
- Volunteers
- 218 people
- Sponsor
- Ellodi Pharmaceuticals, LP
Asthma
Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)
The aim of the study is to compare the effect of ciclesonide on quality of life, pulmonary function and time to first exacerbation in patients with moderate persistent asthma.
- Trial name
- NCT00305461
- Testing
- Ciclesonide
- Where
- 12 sites in Argentina
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Asthma
A Study of 2 Doses of MAP0010 in Adult Asthmatics
The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.
- Trial name
- P202 (NCT00554970)
- Testing
- MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Allergan
Asthma, Exercise-Induced
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
The purpose of this Phase III, multicentre, randomized, double-blind, single-dose, 2-period, crossover study is to assess the efficacy and safety of PT027 (budesonide/albuterol sulfate) metered-dose inhaler compared with placebo…
- Trial name
- BREATH (NCT06245551)
- Testing
- Budesonide/albuterol metered-dose inhaler 160/180 μg
- Where
- 6 sites in Russia
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.